BioTech IP Review

1. Publication Number: US20240010988A1
2. Filing Date: August 11, 2022 (Priority via provisional filings)
3. Publication Date: January 11, 2024 (this application remains active into 2025)
4. Assignee / Applicant: Sana Biotechnology, Inc.
5. Inventors: Sonja Schrepfer, Xiaomeng Hu, et al.

---

What It Covers

This patent application describes engineered primary cells with multiple genetic modifications designed for allogeneic (off-the-shelf) cell therapy — meaning they can be administered into genetically unmatched recipients without triggering strong immune rejection.

• Hypoimmunogenic engineered cells: Cells (e.g., islet cells, T cells, NK cells, stem cells) modified to reduce or eliminate expression of major histocompatibility complex (MHC) class I and/or class II molecules, which ordinarily trigger immune recognition.
• Tolerogenic factor expression: Cells genetically engineered to increase expression of tolerogenic factors such as CD47, PD-L1, HLA-E, HLA-G, CCL21, FasL, SERPINB9, CD200, Mfge8, etc. — which help the cells evade or dampen immune detection and activation after transplantation.
• Immune evasion function: These hypoimmunogenic modifications result in cells that, upon administration, elicit lower immune activation or even avoid systemic T-cell and antibody responses, improving engraftment and persistence in recipients without chronic immunosuppressive drugs.
• Therapeutic use: Methods of administering these engineered cell populations to treat diseases or conditions (e.g., diabetes, cancer, autoimmune and degenerative diseases) where durable cell engraftment and therapeutic function are needed but limited by host immune rejection.

---

Why This Patent Is Important

1. Foundation of Sana’s Allogeneic Cell Therapy Platform

This IP represents a platform technology enabling Sana’s flagship programs that aim to create off-the-shelf cell therapies capable of evading immune rejection — a key differentiator from conventional autologous (patient-specific) approaches that require costly manufacturing and immunosuppression.

2. Broad Therapeutic Applicability

The engineered cells covered aren’t limited to a single cell type: they include islet cells for type 1 diabetes, CAR-T and NK cells for immuno-oncology, and potentially other primary cell types for autoimmune, degenerative, or genetic diseases — multiplying potential commercial indications.

3. Competitive Barrier & Venture Value

If granted into 2025-26, this patent (and its continuations) would help Sana exclude competitors from using similar hypoimmunogenic designs in allogeneic cell therapies and create a stronger negotiating position for partners or acquirers.

4. Supports High-Value Programs

The patent underpins data — such as clinical results showing persistence of engineered pancreatic islet cells in type 1 diabetes without immunosuppression — demonstrating real clinical utility of the claimed platform.

---

Summary

US20240010988A1, published in January 2024 and active through 2025, defines engineered primary (hypoimmunogenic) cells with genetic modifications that reduce immune rejection while increasing tolerogenic signals. This platform is central to Sana Biotechnology’s ambition to deliver off-the-shelf allogeneic cell therapies for a range of diseases — representing one of its most strategically important and potentially valuable pieces of intellectual property.